Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

20/20 Biolabs Q3 2026 Results: Net Loss of $1.38M, Loss Widens

For the nine months ended September 30, 2026, 20/20 Biolabs, Inc. reported a net loss of $5.06 million on revenues of $1.46 million, compared to a net loss of $2.43 million on revenues of $1.51 million in the prior year period. The company experienced a significant increase in operating expenses, primarily driven by sales, general, and administrative costs, and underwent a major capital restructuring involving the conversion of multiple preferred stock series into common stock.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.40.4
Gross profit0.10.1
Net income-1.4-0.8
EPS (diluted, $ a share)$-0.12$-0.17

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-9.0%
Gross margin25.5%
Operating margin-365.6%
Source

10-Q filed with the SEC, NASDAQ: AIDX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

20/20 Biolabs, Inc.: key numbers

Share price
$0.1874Close, Nov 17
Market cap
$2.62M
Shares outstanding
13.99MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Testing LaboratoriesSIC 8734

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from 20/20 Biolabs, Inc.

All →
4:42 PM ET 8-K
Financial Results

20/20 Biolabs Financial Results

20/20 Biolabs reported its Q3 2026 financial results, highlighted by a 4.1% increase in OneTest revenue to $1.36 million for the first nine months of the year and a gross margin expansion to 32.8%. The company ended the quarter with $3.63 million in cash and no debt, while securing a new two-year firefighter cancer screening contract with the state of Vermont expected to contribute to revenue in Q4.

Term
Q3 2026

“OneTest™ revenue grew 4.1% through the first nine months of the year, with gross profit increasing 15.6%. While third quarter revenue was below the prior year, much of this reflected the timing of our state-funded firefighter cancer screening programs. Maryland completed a significant portion of its testing in the second quarter, while the start of Vermont’s program shifted into the fourth quarter. Vermont has now executed its two-year contract, and we expect testing to begin contributing to revenue before year-end.”

Jonathan Cohen, President and Chief Executive Officer

“We ended the third quarter with $3.63 million in cash and no outstanding borrowings, compared to $1.03 million in cash at year-end 2025. Our net loss narrowed to $1.38 million from $1.51 million in the second quarter, while operating expenses declined 4.0% sequentially.”

Alan Bergman, Chief Financial Officer
4:05 PM ET 8-K
Shareholder Meeting

20/20 Biolabs Shareholder Meeting

20/20 Biolabs, Inc. reported the results of its adjourned annual meeting of stockholders held on September 16, 2026. Stockholders approved a charter amendment to increase the number of authorized shares of common stock from 50 million to 500 million shares.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.